Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | BRAF | P15056 | 2/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.44 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4838274 | 1.00 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4839923 | 0.94 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4839934 | 0.94 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4837732 | 0.94 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4837741 | 0.94 | RAB9A (0.52) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4841961 | 0.94 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4841947 | 0.94 | RAB9A (0.49) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4844284 | 0.91 | RXFP1 (0.55) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4844272 | 0.91 | RXFP1 (0.55) | NPC1RAB9ASMN1; SMN2TP53ALDH1A1 | |
| SCHEMBL4842225 | 0.90 | RXFP1 (0.49) | NPC1RAB9ABRAFKCNK3KCNK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378428-B2 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2008-05-27 | — | — | US | disclosed |
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222138-A1 | Nitrogen-containing bicyclic compounds and drugs containing the same as the active ingredient | PARK7, MMP8, CDK7 | NPC1 985/4885RAB9A 2220/4885SMN1; SMN2 144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.